(Q44862237)

6 December 2017

Vaccine manufacturing: challenges and solutions (English)

1 reference

6 December 2017

1 reference

3

Rino Rappuoli

1 reference

6 December 2017

Jeffrey B Ulmer

1

1 reference

PubMed ID

17093488

6 December 2017

Ulrich Valley

series ordinal

2

1 reference

6 December 2017

1 November 2006

1 reference

6 December 2017

1 reference

6 December 2017

24

1 reference

6 December 2017

1377-1383

1 reference

6 December 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt1261

6 December 2017

0 references

cites work

The business of making vaccines

1 reference

7 January 2021

Key drivers behind the development of global vaccine market.

1 reference

7 January 2021

Medicine. The intangible value of vaccination

1 reference

7 January 2021

Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis.

1 reference

7 January 2021

Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits

1 reference

7 January 2021

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

1 reference

7 January 2021

Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58

1 reference

7 January 2021

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

1 reference

7 January 2021

Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6

1 reference

7 January 2021

Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine

1 reference

7 January 2021

Genetic stability of live, cold-adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process

1 reference

7 January 2021

Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses

1 reference

7 January 2021

Amino acid sequence identity between the HA1 of influenza A (H3N2) viruses grown in mammalian and primary chick kidney cells

1 reference

7 January 2021

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

1 reference

7 January 2021

Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system.

1 reference

7 January 2021

An improved reverse genetics system for influenza A virus generation and its implications for vaccine production

1 reference

7 January 2021

1 reference

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

1 reference

7 January 2021

Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.

1 reference

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

7 January 2021

Gene-based vaccines: recent technical and clinical advances

1 reference

7 January 2021

Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic.

1 reference

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

7 January 2021

Plant-derived vaccines against diarrheal diseases

1 reference

7 January 2021

Immunogenicity in humans of an edible vaccine for hepatitis B.

1 reference

7 January 2021

Targeting the innate immune response with improved vaccine adjuvants

1 reference

7 January 2021

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

1 reference

7 January 2021

Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults

1 reference

7 January 2021

Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.

1 reference

7 January 2021

Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency

1 reference

7 January 2021

Topical imiquimod: mechanism of action and clinical applications

1 reference

7 January 2021

Mitigation strategies for pandemic influenza in the United States.

1 reference

7 January 2021

Identifiers

DOI

10.1038/NBT1261

1 reference

6 December 2017

1 reference

PubMed ID

17093488